An Inventisbio Co. Ltd. and Inventisbio LLC patent discloses new phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS) and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities (CLOVES syndrome).
Asieris Pharmaceuticals Co. Ltd. has synthesized new protein arginine N-methyltransferase 5 (PRMT5) inhibitors described as potentially useful for the treatment of bladder cancer.
Tyk Medicines Inc. has patented new cyclin-dependent kinase 2 (CDK2) and/or cyclin-dependent kinase 4 (CDK4) inhibitors reported to be useful for the treatment of cancer, infections, metabolic diseases, cardiovascular, inflammatory and immunological disorders.
Several Gluetacs Therapeutics (Shanghai) Co. Ltd. patents describe molecular glue degraders reported to be useful for the treatment of cancer, anemia, liver failure, diabetes, infections, sarcoidosis, autoimmune diseases and cardiovascular disorders.
Previous research has shown that cell division cycle associated 4 (CDCA4) is overexpressed in multiple tumors and is involved in tumor progression. Researchers from Yangtze University and affiliated organizations investigated the role of CDCA4 in bladder cancer.
Microglia play a crucial role in neuroinflammation after ischemic brain injury. Previous data have shown that leukocyte immunoglobulin-like receptor B4 (LILRB4) was upregulated in mice after middle cerebral artery occlusion (MCAO), but the role it plays here is not well understood. The role LILRB4 plays in ischemic brain injury was thus investigated. LILRB4 expression was measured in mice at different time points after MCAO.
Leishmaniasis is a life-threatening parasitic infection and one of the most concerning neglected vector-borne tropical diseases worldwide. Current leishmaniasis chemotherapeuticals are poorly effective and cause significant adverse effects. Metal-containing drugs have been little explored as antibacterial and antiparasitic agents, although some have shown promise against Leishmania.
Ulcerative colitis is a chronic, immune-mediated disorder of the colon and rectum characterized by mucosal inflammation that damages the bowel wall surface. Current therapeutic options include 5-aminosalicylates, corticosteroids or anti-TNF agents, but there is a need for new strategies to obtain higher remission rates and less systemic immunosuppression.
Researchers from the Centre for Addiction and Mental Health (CAMH) and affiliated organizations presented preclinical data for the α5-GABA-A receptor (α5-GABAAR) positive allosteric modulator GL-II-73 (DPX-101), which is being developed by Damona Pharmaceuticals Inc. for the treatment of Alzheimer’s disease and other cognitive and neurological disorders.
RSS
